Sign In
Buy ABUS
$4.26
-0.220 (-4.91%)
At Close: Jun 02, 2026
Arbutus Provides 2025 Corporate and Financial Update
07:30am, Monday, 13'th Jan 2025
Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon
Arbutus: Positive Imdusiran Data Leads To Phase 2B Development
07:56am, Tuesday, 07'th Jan 2025
Company's phase 2a trial of Imdusiran with pegylated interferon alfa-2a achieved a functional cure in 25% of Hepatitis B patients. The company is developing its own in-house oral PD-L1 inhibitor, AB-1
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
07:30am, Tuesday, 26'th Nov 2024
WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensi
Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
11:02am, Friday, 15'th Nov 2024
50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial
Significantly greater mean declines in HBsAg levels (p
Arbutus to Present at Jefferies London Healthcare Conference
07:30am, Thursday, 14'th Nov 2024
WARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensi
Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript
02:52pm, Wednesday, 06'th Nov 2024
Arbutus Biopharma Corporation (NASDAQ:ABUS ) Q3 2024 Results Conference Call November 6, 2024 8:45 AM ET Company Participants Lisa Caperelli - VP, Investor Relations Mike McElhaugh - Interim President
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates
09:46am, Wednesday, 06'th Nov 2024
Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.12 per share a year ago.
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
07:30am, Wednesday, 23'rd Oct 2024
WARMINSTER, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensiv
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
08:16am, Tuesday, 15'th Oct 2024
WARMINSTER, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensiv
Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year?
10:47am, Wednesday, 25'th Sep 2024
Here is how Arbutus Biopharma (ABUS) and Astrazeneca (AZN) have performed compared to their sector so far this year.
Arbutus to Participate in Two Upcoming Investor Conferences
07:30am, Tuesday, 03'rd Sep 2024
WARMINSTER, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensi
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?
10:40am, Thursday, 22'nd Aug 2024
Here is how Arbutus Biopharma (ABUS) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year.
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
10:41am, Tuesday, 06'th Aug 2024
Here is how Arbutus Biopharma (ABUS) and Annexon, Inc. (ANNX) have performed compared to their sector so far this year.
Arbutus Layoffs 2024: What to Know About the Latest ABUS Job Cuts
03:03pm, Thursday, 01'st Aug 2024
Biotechnology firm Arbutus (NASDAQ: ABUS ) — which specializes in virology — announced a major overhaul of its business. It will dramatically cut headcount in an effort to streamline operations an
